[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369987-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369987-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","perioperative-nivolumab-or-nivolumab-plus-ipilimumab-in-resectable-diffuse-pleural-mesothelioma-a-phase-2-trial-and-ctdna-analyses","Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma - a phase 2 trial and ctDNA analyses","","Immune checkpoint blockade is standard for advanced diffuse pleural mesothelioma, yet its perioperative role and how to monitor residual disease remain unclear. A phase 2 trial evaluated neoadjuvant nivolumab or nivolumab plus ipilimumab with tumor-informed ctDNA residual disease assessment in resectable epithelioid or biphasic disease. The study met primary safety and feasibility endpoints, with most patients proceeding to surgery. Persistent ctDNA during neoadjuvant therapy identified patients with progression-associated non-complete resection and shorter PFS. Results support perioperative ICB feasibility and ctDNA analysis utility for residual disease capture.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/perioperative-nivolumab-or-nivolumab-plus-ipilimumab-in-resectable-diffuse-pleural-mesothelioma-a-phase-2-trial-and-ctdna-analyses/369987/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/perioperative-nivolumab-or-nivolumab-plus-ipilimumab-in-resectable-diffuse-pleural-mesothelioma-a-phase-2-trial-and-ctdna-analyses/369987.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of this phase 2 trial?","Question",{"text":63,"@type":64},"To evaluate the feasibility and safety of neoadjuvant perioperative immune checkpoint blockade in resectable diffuse pleural mesothelioma and to assess tumor-informed ctDNA for residual disease detection and clinical correlation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the two treatment arms differ?",{"text":68,"@type":64},"Arm A received nivolumab every 2 weeks for three cycles, while Arm B received nivolumab plus ipilimumab during cycle 1, then continued with nivolumab before surgery and a year of maintenance dosing.",{"name":70,"@type":61,"acceptedAnswer":71},"What did ctDNA reveal about residual disease and outcomes?",{"text":72,"@type":64},"Persistent ctDNA during neoadjuvant therapy occurred in patients who did not undergo complete surgical resection due to progression, and detectable ctDNA around cycle 3 and pre-surgery was associated with shorter progression-free survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369987,1790216834,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| nature medicine |  | |\n| --- | --- | --- |\n| Article [https://doi.org/10.1038/s41591-025-03958-3](https://doi.org/10.1038/s41591-025-03958-3) |  |  |\n| Perioperative nivolumabornivolumab plus ipilimumabin resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses |  |  |\n| Received: 18 July 2025\u003Cbr>Accepted: 13 August 2025\u003Cbr>Published online: 8 September 2025  Check for updates | A list of authors and their affiliations appears atthe end of the paper\u003Cbr>Immune checkpoint blockade (ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioperative management ofDPMis unclear. In tandem, circulating tumor DNA (ctDNA) ultra-sensitive residual disease detection has shown promise in providing a molecular readout ofICB efficacy across resectable cancers. This phase 2 trial investigated neoadjuvant nivolumaband nivolumab/ipilimumabin resectable DPM along with tumor-informed liquid biopsy residual disease assessments. Patients with resectable epithelioid/biphasic DPM enrolled sequentially to nivolumab 240 mg every 2 weeks (q2w) for three cycles (ArmA, n = 16) or nivolumab 3 mg kg−1 q2w for three cycles plus ipilimumab 1 mg kg−1 on cycle 1 (Arm B, n = 14), followed by surgery, optional chemotherapy and/or radiotherapy, and nivolumab 480 mg q4w for 1 year. Co-primary endpoints included safety and feasibility; key exploratory endpoints included progression-free survival (PFS), overall survival (OS) and ctDNA analyses. The trial met its primary endpoints, and, in Arms A and B, 81.3% and 85.7% of patients proceeded to surgery, respectively. Treatment was safe, with a single dose-limiting toxicity in each arm. In ArmA, median PFSand OS were 9.6 months (95% confidence interval (CI): 2.5–27.7) and 19.3 months (95% CI: 14.9–34.7), respectively. In Arm B, median PFSand OS were 19.8 months (7.1–not reached) and 28.6 months (20.4–not reached), respectively. Persistent ctDNA was detected during neoadjuvant therapy inpatients who did not undergo complete surgical resection due to disease progression (Fisher’sexact test, P = 0.00013). Patients with detectable ctDNA on cycle 3 and pre-surgery had shorter PFS (log-rank test, P = 0.027 and P = 0.0059, respectively); this association was more pronounced when quantitative ctDNA changes were considered (log-rank test, P = 1.8 × 10−6). Our findings support the feasibility of neoadjuvantICBand the clinical utility of ctDNA analyses to capture residual disease in resectable DPM. ClinicalTrials.gov identifier: NCT03918252. |  |\n\n[e-mail:](e-mail: vanagno1@jhmi.edu)[ vanagno1@jhmi.edu](e-mail: vanagno1@jhmi.edu); [fordep1@tcd.ie](fordep1@tcd.ie)  \nDPM is a rare malignancy of the pleural lining that is diagnosed in approximately 30,000 individuals worldwide annually, with increased incidence in regions with high asbestos exposure1. DPMis incurable inmost cases and for decades encountered little innovation in systemic therapy. However, this changed with the emergence ofICB, and in the phase 3 CheckMate 743 trial, the combination of the anti-PD-1 antibody nivolumab (nivo) plus anti-CTLA-4 antibody ipilimumab (ipi) demonstrateda significant OS benefit over platinum doublet chemotherapy in treatment-naive unresectable DPM2,3. Similarly, the phase 3 IND227 trial showed a significant OS advantage with the combination of the anti-PD-1 agent pembrolizumaband platinum doublet chemotherapy compared to chemotherapy alone in advanced, treatment-naive, unresectable DPM4. Both combinatorial strategies are now approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as frontline therapies forDPM, with pembrolizumab plus chemotherapy approved by theEMA only for non-epithelioid DPM.  \nThe management of potentially resectable DPM is complex and controversial. Several retrospective and small single-arm studies using an aggressive tri-modality approach, including perioperative chemotherapy, surgery and radiotherapy, have shown clinical ","cbCaif9xokZsTztL","https://ap.wps.com/l/cbCaif9xokZsTztL","pdf",8099127,33,"English","# Background and rationale\n## Rarity and prior standard therapies\n## Controversy in potentially resectable management\n## Need for perioperative immune checkpoint blockade\n# Trial design and treatments\n## Study arms and dosing schedules\n## Surgical and adjuvant/optional modalities\n# Endpoints and outcomes\n## Primary safety and feasibility\n## Progression-free survival and overall survival by arm\n# ctDNA analyses and clinical correlations\n## Residual disease detection during neoadjuvant therapy\n## Associations with progression-free survival\n# Conclusions","[{\"question\":\"What was the main purpose of this phase 2 trial?\",\"answer\":\"To evaluate the feasibility and safety of neoadjuvant perioperative immune checkpoint blockade in resectable diffuse pleural mesothelioma and to assess tumor-informed ctDNA for residual disease detection and clinical correlation.\"},{\"question\":\"How did the two treatment arms differ?\",\"answer\":\"Arm A received nivolumab every 2 weeks for three cycles, while Arm B received nivolumab plus ipilimumab during cycle 1, then continued with nivolumab before surgery and a year of maintenance dosing.\"},{\"question\":\"What did ctDNA reveal about residual disease and outcomes?\",\"answer\":\"Persistent ctDNA during neoadjuvant therapy occurred in patients who did not undergo complete surgical resection due to progression, and detectable ctDNA around cycle 3 and pre-surgery was associated with shorter progression-free survival.\"}]","Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma - a phase 2 trial and ctDNA analyses | PDF",1790186166,83,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/800c8051bfb9494c49d0949a389e6a0a.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/701f942ef25b08951e7905bffca900ef.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38ad3c2cc871fb6f028dc0477675ba77.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e91ef7ed7b190ba46170ed3d9a0560b9.webp",980,1301]